ClinicalTrials.Veeva

Menu

Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases

Chinese Academy of Medical Sciences & Peking Union Medical College logo

Chinese Academy of Medical Sciences & Peking Union Medical College

Status

Enrolling

Conditions

Hypertension
Chronic Kidney Diseases
Hyperuricemia
Diabetes Mellitus
Obesity

Treatments

Diagnostic Test: Biomarkers

Study type

Observational

Funder types

Other

Identifiers

NCT05476627
JS-2136

Details and patient eligibility

About

With the development of China's economy, people's living standard have improved, and the dietary structure have changed. Metabolic diseases, such as hypertension, diabetes, hyperuricemia and obesity have gradually become an important health burden in China. The pathophysiological mechanism of renal injury caused by metabolic diseases has always been a hotspot of research. Currently, it is believed that various mechanisms including the activation of Renin-Angiotensin-Aldosterone System, vascular endothelial dysfunction, oxidative stress and inflammatory process may be involved. Although there are differences in renal pathological manifestations caused by different metabolic diseases, the kidney will eventually present ischemic changes and fibrosis with the progression of the disease. So there must be some common pathogenesis. This study is designed to build a disease cohort of patients with chronic kidney disease caused by metabolic diseases, to identify risk factors leading to disease progression and to explore biomarkers for early diagnosis and treatment of kidney damage.

Enrollment

200 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • The diagnosis of metabolic diseases were confirmed;
  • Be able to understand the process of the research;
  • Volunteer for participation and be able to sign the informed consent.

Exclusion criteria

  • Age <18 yrs or >80yrs;
  • Patients with primary and secondary glomerular diseases
  • Patients with other comorbidities that could affect the volume or the components of the kidney, such as renal cysts, polycystic kidney disease, medullary sponge kidney, hydronephrosis, renal artery stenosis, renal vein thrombosis and/or renal tumors;
  • Contraindications for MRI examination;
  • Pregnant or lactation patients;
  • Patients with unstable vital signs, failure of other organs or dysphoria.

Trial design

200 participants in 4 patient groups

Hypertension Group
Treatment:
Diagnostic Test: Biomarkers
Diabetes Group
Treatment:
Diagnostic Test: Biomarkers
Hyperuricemia
Treatment:
Diagnostic Test: Biomarkers
Obesity
Treatment:
Diagnostic Test: Biomarkers

Trial contacts and locations

1

Loading...

Central trial contact

Yan Liu

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems